Cyteir Therapeutics

General Information

We are a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together. Our lead program, CYT-0851, as well as our next generation drug candidate CYT-1853, exploits a novel gain-of-function synthetically lethal relationship between overexpression of a family of DNA damaging genes called cytidine deaminases, or CDs, and functional inhibition of homologous recombination, or HR, a DNA repair pathway critical for the survival of some cancers. CYT-0851 is a novel, oral small molecule inhibitor of RAD51-mediated HR and, to our knowledge, is the only such inhibitor of RAD51-mediated HR in clinical development. 

(Note: Cyteir Therapeutics priced its IPO on June 17, 2021, at $18 – the top of its $16-to-$18 range – on 7.4 million shares, the same number as in the prospectus, to raise 

Employees: 31
Founded: 2012
Contact Information
Address 128 Spring St, Building A, Suite 510, Lexington, MA 02421, USA
Phone Number 857-285-4140
Web Address
View Prospectus: Cyteir Therapeutics
Financial Information
Market Cap $585.99mil
Revenues $0 mil (last 12 months)
Net Income $-22.2 mil (last 12 months)
IPO Profile
Symbol CYT
Exchange NASDAQ
Shares (millions): 7.4
Price range $18.00 - $18.00
Est. $ Volume $133.2 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ BofA Securities
CO-Managers Wedbush Securities
Expected To Trade: 6/18/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change